Shared Decision Making on Radiation Dose for Stereotactic Body Radiotherapy of Malignancies Located Less Than 1 cm From the Thoracic Wall. A Randomized Trial

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A Patient Decision Aid (PtDA) is developed during a workshop in close collaboration with selected patients. The PtDA is subsequently used in the consultation between patient and physician to facilitate their shared decision on the dose of stereotactic body radiation therapy (SBRT) for lung tumors located less than 1 cm from the thoracic wall. Hypothesis: The use of a PtDA will increase the extent of Shared Decision Making (SDM) during the consultation and result in patients being more directly involved in the planning of their treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• Histologically confirmed or high probability of non-small cell lung cancer, or metastasis from other cancer, located ≤ 1 cm from the thoracic wall. High probability refers to consensus on the diagnosis at the local multi-disciplinary lung tumor conference.

• Eligible for stereotactic body radiation therapy in ablative doses (i.e. 66/45 Gy in 3 fractions) following national guidelines (2).

• Can read and understand Danish.

• Written and orally informed consent.

• Performance status 0-2

• Life expectancy \> 6 months assessed by the physician during the consultation.

Locations
Other Locations
Denmark
Vejle Hospital, Department of Oncology
RECRUITING
Vejle
Contact Information
Primary
Thomas L Fink, MD
thomas.leth.fink@rsyd.dk
+4579405446
Time Frame
Start Date: 2021-11-12
Estimated Completion Date: 2030-08-31
Participants
Target number of participants: 40
Treatments
No_intervention: A - control
The patients are offered high or lower dose according to usual practice
Experimental: B - Intervention
The Patient Decision Aid is used during the consultation to aid in the decision on high or lower dose.
Sponsors
Leads: Vejle Hospital

This content was sourced from clinicaltrials.gov